Adaptive Designs in Clinical Trials 2019

SMi Group are proud to announce the 11th annual Adaptive Designs in Clinical Trials conference and exhibition will return to London from the 1st – 2nd April 2019. With the growing popularity in use and acceptance of adaptive designs in clinical trials - demonstrated most recently with the new FDA draft guidance on adaptive designs – there is a pressing need for a forum which explores this increasingly normalized medical methodology.

Hosting in depth presentations from regulatory agencies, researchers and biostatisticians, the meeting will cover how personalized medicine, platform trials, response-adaptive randomization, signature designs, estimand framework, Bayesian methods and digital innovation are revolutionizing the drug development process both in Europe and North America.

The benefits of attending:

At this year’s conference there will once again be an array of networking opportunities:

Meet and network with key industry and thought leaders shaping state of the art adaptive design techniques
More than 4 hours of networking during the conference days
Engage with an array of vendors, with leading solution providers, Mevia and GCE Solutions among those exhibiting last year

Key reasons to attend:

See how the regulatory environment for adaptive drug design is shifting across the continent with insights from the MHRA, Amgen, AstraZeneca and Berry Consulting
Explore the therapeutic potential of adaptive designs with real-world examples from H.Lundbeck, GSK Vaccines, Pfizer and Novartis
Listen to how the latest platform trial case studies – such as that of the EPAD project and the MS Society initiative, are impacting pharmaceutical development
Delve into the long-standing discussion of Bayesian vs. frequentist designs
Discover the latest research in response-adaptive designs: trials for rare diseases and looking forward

Chairs for 2019:

Alex Sverdlov, Director, Statistical Scientist, Novartis

Tom Parke, Director of Software Solutions, Berry Consulting

Featured Speakers:

Sandeep Menon, Vice President and Head of Early Clinical Development, Pfizer
Simon Wandel, Associate Director, Statistical Methodology and Consulting, Novartis
Solange Corriol-Rohou, Senior Director Regulatory Addairs & Policy, Europe, AstraZeneca*
Christine Fletcher, Executive Director Biostatistics, Amgen
Philip Hougaard, Vice President Biometrics, H. Lundbeck
Beatrice Panico, Medical Assessor, MHRA
Kaspar Rufi bach, Principal Statistical Scientist, Roche
Andrea Callegaro, Senior Manager, Biostatistician, GSK Vaccines